Dosage of Dyrk1a shifts cells within a p21-cyclin D1 signaling map to control the decision to enter the cell cycle. Academic Article uri icon

Overview

abstract

  • Mammalian cells have a remarkable capacity to compensate for heterozygous gene loss or extra gene copies. One exception is Down syndrome (DS), where a third copy of chromosome 21 mediates neurogenesis defects and lowers the frequency of solid tumors. Here we combine live-cell imaging and single-cell analysis to show that increased dosage of chromosome 21-localized Dyrk1a steeply increases G1 cell cycle duration through direct phosphorylation and degradation of cyclin D1 (CycD1). DS-derived fibroblasts showed analogous cell cycle changes that were reversed by Dyrk1a inhibition. Furthermore, reducing Dyrk1a activity increased CycD1 expression to force a bifurcation, with one subpopulation of cells accelerating proliferation and the other arresting proliferation by costabilizing CycD1 and the CDK inhibitor p21. Thus, dosage of Dyrk1a repositions cells within a p21-CycD1 signaling map, directing each cell to either proliferate or to follow two distinct cell cycle exit pathways characterized by high or low CycD1 and p21 levels.

publication date

  • October 10, 2013

Research

keywords

  • Cell Proliferation
  • Cyclin D1
  • Cyclin-Dependent Kinase Inhibitor p21
  • G1 Phase
  • Protein Serine-Threonine Kinases
  • Protein-Serine-Threonine Kinases
  • Protein-Tyrosine Kinases

Identity

PubMed Central ID

  • PMC4039290

Scopus Document Identifier

  • 84885334501

Digital Object Identifier (DOI)

  • 10.1016/j.molcel.2013.09.009

PubMed ID

  • 24119401

Additional Document Info

volume

  • 52

issue

  • 1